A detailed history of Baker Tilly Wealth Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baker Tilly Wealth Management, LLC holds 2,289 shares of VRTX stock, worth $1.18 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
2,289
Previous 1,888 21.24%
Holding current value
$1.18 Million
Previous $884,000 20.36%
% of portfolio
0.48%
Previous 0.37%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$460.0 - $505.78 $184,460 - $202,817
401 Added 21.24%
2,289 $1.06 Million
Q2 2024

Jul 18, 2024

SELL
$392.81 - $485.53 $345,672 - $427,266
-880 Reduced 31.79%
1,888 $884,000
Q1 2024

May 09, 2024

BUY
$407.69 - $446.08 $17,122 - $18,735
42 Added 1.54%
2,768 $1.16 Million
Q4 2023

Jan 10, 2024

SELL
$343.0 - $410.68 $195,167 - $233,676
-569 Reduced 17.27%
2,726 $1.11 Million
Q3 2023

Oct 10, 2023

SELL
$338.18 - $362.46 $2.18 Million - $2.33 Million
-6,439 Reduced 66.15%
3,295 $1.15 Million
Q2 2023

Jul 20, 2023

BUY
$314.42 - $351.91 $78,290 - $87,625
249 Added 2.63%
9,734 $3.43 Million
Q1 2023

Apr 12, 2023

SELL
$283.23 - $323.1 $77,605 - $88,529
-274 Reduced 2.81%
9,485 $2.99 Million
Q4 2022

Jan 26, 2023

BUY
$285.76 - $321.48 $251,468 - $282,902
880 Added 9.91%
9,759 $0
Q3 2022

Oct 20, 2022

BUY
$273.83 - $305.53 $136,367 - $152,153
498 Added 5.94%
8,879 $2.57 Million
Q2 2022

Jul 28, 2022

SELL
$234.96 - $292.55 $211,698 - $263,587
-901 Reduced 9.71%
8,381 $2.36 Million
Q1 2022

Apr 27, 2022

BUY
$221.42 - $260.97 $334,344 - $394,064
1,510 Added 19.43%
9,282 $2.42 Million
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $191,347 - $241,549
1,081 Added 16.16%
7,772 $1.71 Million
Q3 2021

Nov 02, 2021

BUY
$181.39 - $202.99 $1.21 Million - $1.36 Million
6,691 New
6,691 $1.21 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Baker Tilly Wealth Management, LLC Portfolio

Follow Baker Tilly Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Tilly Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baker Tilly Wealth Management, LLC with notifications on news.